Higher values of SAT2 (targeted by trientine, which is in phase 2 clinical development for hypertrophic cardiomyopathy) and NUDT9 associated with lower DCM risk, while FCG3A (the target of imgatuzumab) and CACP (targeted by levocarnitine, which is being tested for AF and HF) associated with higher DCM risk. This evidence concerns the gene SAT2 and hydrops fetalis.